Eledon Pharmaceuticals, Inc. (ELDN)

Over the past six months, Eledon reported a narrower loss in its second quarter earnings. The stock plunged 52.2% after announcing mixed results from its Phase 2 BESTOW clinical trial, but positive results from the efficacy failure composite endpoint and a favorable safety profile led the company to plan for Phase 3 development. Eledon reported its third-quarter 2025 results, reiterating the favorable safety and tolerability profile of tegoprubart and highlighting a strengthened balance sheet due to $57.5 million in financing. Guggenheim maintained a "Buy" recommendation for Eledon Pharmaceuticals. The stock experienced gains in after-hours trading due to biotech momentum. ELDN's price moved over +5.00%. The stock price fell below its 15-day moving average on both days. The closing stock price was $1.97. The stock was trading at $2.19 in the after-hours session. The stock's 52-week high was $4.97 and its 52-week low was $1.35.

Information regarding specific demand seasonality for Eledon Pharmaceuticals, Inc.'s products and services is not readily available. Identifying such patterns would typically require historical insights and specialized data on market seasonality.

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases characterized by smooth muscle dysfunction, transplantation, and autoimmune conditions. The company utilizes a proprietary ion-channel modulation platform and immunology expertise to target the CD40 Ligand (CD40L) pathway. Its primary therapeutic areas include gastrointestinal, hepatic, and cardiovascular disorders, transplantation, autoimmune diseases, and ALS. The major product in Eledon's pipeline is tegoprubart, an anti-CD40L antibody being developed for various applications, including the prevention of allograft rejection in kidney transplantation, islet cell transplantation, xenotransplantation, IgA Nephropathy (IgAN), and ALS. The company has completed the global Phase 2 BESTOW clinical trial for tegoprubart in preventing kidney transplant rejection and is conducting an ongoing Phase 1b clinical trial for the same indication, as well as exploring its potential in liver transplantation.

Eledon Pharmaceuticals, Inc. is based in the United States and maintains operations in Europe. The company conducts multi-center studies across North America and the EMEA region. Currently, Eledon's cell manufacturing efforts are focused on a site in Chicago.

Eledon Pharmaceuticals has a consensus rating of "Hold" from MarketBeat, based on analyst ratings that include three "buy" ratings, one "hold" rating, and one "sell" rating. Despite the Phase 2 BESTOW trial missing its primary endpoint, the company highlighted that tegoprubart maintained strong renal function and demonstrated a favorable safety profile, which could positively influence its reputation. The company's mission to "transform the lives of patients by bringing groundbreaking treatments to market" and its patient-centric approach also contribute to its brand image.

Eledon Pharmaceuticals, Inc. has 155 institutional owners and shareholders holding a total of 40,849,618 shares. As of September 2025, institutions held 44.23% of the shares outstanding. Major institutional shareholders include BVF Inc/il, Vanguard Group Inc, RA Capital Management, L.P., BlackRock, Inc., Siren, L.L.C., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Zimmer Partners, LP, Geode Capital Management, LLC, Wellington Management Group LLP, and Sphera Funds Management Ltd. VOYA INVESTMENT MANAGEMENT LLC was identified as a primary institutional investor as of September 30, 2025, holding 11.42K shares, representing 0.02% of the stock.